surpass 2 tirzepatide Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the Clinical Trial Program | Cardiovascular Diabetology Tirzepatide for diabetes: on track

The Topline - Individuals with knee osteoarthritis lost record setting weight loss for the highly effective obesity medications and reduced their knee pain

2024;13(21):e2302682

I had tried everything for years

Important precautions Severe stomach or bowel problems Mounjaro can cause severe dehydration due to vomiting and diarrhoea

Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should be counselled about this risk Patient safety advice for those using GLP-1 receptor agonists includes: Report persistent nausea, vomiting, or abdominal pain to your GP promptly Stop treatment and seek urgent medical care if you develop severe, persistent abdominal pain that may suggest pancreatitis Maintain adequate hydration, especially during initial treatment and if experiencing vomiting or diarrhoea Monitor for signs of gallbladder problems (sustained upper right abdominal pain, fever, jaundice) Patients with diabetes should monitor blood glucose levels closely, particularly when starting treatment or adjusting doses Inform healthcare providers of all medications to assess interaction risks Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app Pregnant women or those planning pregnancy should not use GLP-1 receptor agonists